Istituto Nazionale per le Ricerche Cardiovascolari, University of Modena & Reggio Emilia, 41124 Modena, Italy.
Cardiology Division, Policlinico di Modena, 41124 Modena, Italy.
Future Cardiol. 2021 May;17(3):487-496. doi: 10.2217/fca-2021-0011. Epub 2021 Mar 19.
Cardiovascular disease (CVD) is the leading cause of death among men and women, although women are usually underdiagnosed and experience a delay in diagnosis. This also occurs in women with type 2 diabetes mellitus, despite the fact that diabetes is recognized as a major cardiovascular risk factor. Several factors influence the gap between diagnosis and treatment of cardiovascular disease in women: lack of perception of cardiovascular risk, effects of sex-related risk factors and the action of drugs in women. Women with Type 2 diabetes mellitus are more likely to be assigned a lower CVD risk category and to receive lifestyle counseling as well as less intensive CVD therapy compared with men. The present narrative review aims to analyze the risk of CVD in women with Type 2 diabetes mellitus and whether there is a difference between men and women in the efficacy of SGLT-2 inhibitors, new hypoglycemic drugs.
心血管疾病（CVD）是男性和女性的主要死因，尽管女性通常被漏诊并且诊断时间延迟。患有 2 型糖尿病的女性也存在这种情况，尽管糖尿病已被确认为主要心血管危险因素。有几个因素影响女性心血管疾病的诊断和治疗差距：对心血管风险的认识不足、与性别相关的危险因素的影响以及药物在女性中的作用。与男性相比，患有 2 型糖尿病的女性更有可能被归为较低的 CVD 风险类别，并接受生活方式咨询以及不太密集的 CVD 治疗。本叙述性综述旨在分析患有 2 型糖尿病的女性的 CVD 风险，以及新型降糖药物 SGLT-2 抑制剂在男性和女性中的疗效是否存在差异。
